Literature DB >> 8037356

Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine.

O Soyombo1, B W Spur, T H Lee.   

Abstract

Lipoxins are trihydroxytetraene metabolites derived through a double lipoxygenation of arachidonic acid. Lipoxin A4 (LXA4) was prepared by total chemical synthesis, and its capacity to modulate eosinophil migration has been evaluated. LXA4 is a weak and partial chemotactic agent; at 10(-6) M, it achieved about 20% of the response of 10(-6) M platelet-activating factor (PAF). Preincubation of eosinophils with increasing doses of LXA4 (10(-10)-10(-5) M) resulted in a concentration-dependent inhibition of cell migration induced by 10(-6) M formyl-methionyl-leucyl-phenylalanine (FMLP) and 10(-6) M PAF. The concentration of LXA4 which produced 50% inhibition (IC50) of eosinophil migration was approximately 10(-6) M. LXA4 (10(-10)-10(-6) M) did not elicit ECP release or modulate ECP release induced by 10(-6) M FMLP. LXA4 may have antiallergic properties in preventing eosinophilic migration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8037356     DOI: 10.1111/j.1398-9995.1994.tb02654.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  26 in total

1.  Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin.

Authors:  R Scalia; J Gefen; N A Petasis; C N Serhan; A M Lefer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

Review 2.  Endogenous lipid mediators in the resolution of airway inflammation.

Authors:  O Haworth; B D Levy
Journal:  Eur Respir J       Date:  2007-11       Impact factor: 16.671

3.  Phagocytic clearance of apoptotic cells: role in lung disease.

Authors:  Jeong H Yun; Peter M Henson; Rubin M Tuder
Journal:  Expert Rev Respir Med       Date:  2008-12       Impact factor: 3.772

Review 4.  Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases.

Authors:  Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.

Authors:  Paola Maderna; David C Cottell; Tiina Toivonen; Neil Dufton; Jesmond Dalli; Mauro Perretti; Catherine Godson
Journal:  FASEB J       Date:  2010-06-22       Impact factor: 5.191

Review 6.  Lipoxin A4: a novel anti-inflammatory molecule?

Authors:  T H Lee
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

Review 7.  Resolvins: natural agonists for resolution of pulmonary inflammation.

Authors:  Mohib Uddin; Bruce D Levy
Journal:  Prog Lipid Res       Date:  2010-09-29       Impact factor: 16.195

Review 8.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

9.  Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma.

Authors:  Cindy Barnig; Manuela Cernadas; Stefanie Dutile; Xiaoli Liu; Mark A Perrella; Shamsah Kazani; Michael E Wechsler; Elliot Israel; Bruce D Levy
Journal:  Sci Transl Med       Date:  2013-02-27       Impact factor: 17.956

Review 10.  Resolution of inflammation in asthma.

Authors:  Bruce D Levy; Isabelle Vachier; Charles N Serhan
Journal:  Clin Chest Med       Date:  2012-07-25       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.